14.50
0.18 (1.26%)
| Previous Close | 14.32 |
| Open | 14.61 |
| Volume | 236,844 |
| Avg. Volume (3M) | 223,219 |
| Market Cap | 773,895,424 |
| Price / Book | 2.36 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -1.63 |
| Total Debt/Equity (MRQ) | 1.89% |
| Current Ratio (MRQ) | 22.78 |
| Operating Cash Flow (TTM) | -73.20 M |
| Levered Free Cash Flow (TTM) | -37.79 M |
| Return on Assets (TTM) | -19.00% |
| Return on Equity (TTM) | -27.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tyra Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.69% |
| % Held by Institutions | 108.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2025 | 12,198,625 |
| Alta Partners Management Company, L.P. | 30 Sep 2025 | 4,080,296 |
| Nextech Invest, Ltd. | 30 Jun 2025 | 4,055,861 |
| Nextech Invest Ltd. | 31 Dec 2024 | 4,055,861 |
| Canaan Partners Xi Llc | 30 Sep 2025 | 3,608,109 |
| Commodore Capital Lp | 30 Jun 2025 | 3,100,000 |
| Tcg Crossover Management, Llc | 30 Jun 2025 | 2,898,103 |
| Vestal Point Capital, Lp | 30 Jun 2025 | 2,655,000 |
| Kynam Capital Management, Lp | 30 Jun 2025 | 2,329,998 |
| Farallon Capital Management Llc | 30 Jun 2025 | 1,143,818 |
| 5Am Venture Management, Llc | 30 Jun 2025 | 939,298 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Raymond James, 141.38%) | Buy |
| Median | 32.50 (124.14%) | |
| Low | 30.00 (HC Wainwright & Co., 106.90%) | Buy |
| Average | 32.50 (124.14%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 12.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 03 Sep 2025 | 35.00 (141.38%) | Buy | 12.32 |
| HC Wainwright & Co. | 22 Aug 2025 | 30.00 (106.90%) | Buy | 11.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Nov 2025 | Announcement | Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights |
| 21 Aug 2025 | Announcement | Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia |
| 20 Aug 2025 | Announcement | Tyra Biosciences Announces Participation at Upcoming Investor Events |
| 14 Aug 2025 | Announcement | Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |